Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Approves Expanded Indication For Byetta Injection
Amylin Pharmaceuticals (Amylin) and Eli Lilly have reported that the FDA has approved an expanded indication for Byetta (exenatide) injection. Byetta is now approved for use as a
Amylin Pharmaceuticals (Amylin) and Eli Lilly have reported that the FDA has approved an expanded indication for Byetta (exenatide) injection. Byetta is now approved for use as a
Affymax and Takeda Pharmaceutical (Takeda) have reported data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a phase 2 trial, which demonstrated that Hematide
The FDA has issued a complete response letter to Schering-Plough’s supplemental Biologics License Application (BLA) regarding Pegintron (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage
Amgen has published the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a randomised, double-blind and placebo-controlled, phase 3 pivotal study of patients with
Eisai announced preliminary results from a recently completed phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic
Geron is planning to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury. The plan is expected to
FDA has sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally
Warner Chilcott has completed the acquisition of The Procter & Gamble pharmaceutical business(P&G). The acquisition is expected to complement Warner Chilcott’s existing presence in women’s health care and
NovaBay has announced that its Aganocide compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented at the
Impax has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR (fenofibrate) tablets, 48 mg and 145 mg. Impax filed its abbreviated